Office of Health Economics

Report: Growing divide between drug development, healthcare system in U.K.

Friday, April 11, 2014

The Association of the British Pharmaceutical Industry (ABPI) has issued a report that findsover half of the active products in the global industry research pipeline are personalized medicines, and the U.K. healthcare system is at risk of failing to adapt to this new challenge. The report highlights the emergence of specialized medicines as a key challenge for the U.K. pharmaceutical industry and says for the commercial environment in the U.K. to respond to this challenge, a fundamental shift in the Health Technology Assessment (HTA) approaches is needed.

[Read More]

OHE releases new study on pharmaceutical R&D costs

Monday, December 3, 2012

The Office of Health Economics has released a comprehensive study of the cost of R&D for new medicines. It reviews research published over the last three decades, which shows an increase in costs from $199 million per new medicine in the 1970s to $1.9 billion in the 2000s. An OHE costs analysis based on new data for 1998-2002 agrees with comparable analyses for the same time period.

[Read More]